We are live on ! Find out more
SGNT

SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT

Delisted

SGNT was delisted on the 29th of August, 2016.

94 hedge funds and large institutions have $538M invested in SAGENT PHARMACEUTICALS INC COM STK (DE) in 2014 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

4% less capital invested

Capital invested by funds: $560M → $538M (-$21.7M)

5% less funds holding

Funds holding: 9994 (-5)

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
94
Holders Change
-5
Holders Change %
-5.05%
% of All Funds
2.71%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
14
Increased
38
Reduced
32
Closed
19
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
ARC
51
Absolute Return Capital
Massachusetts
$532K +$498K +22,785 New
GA
52
Geneva Advisors
Illinois
$520K
Acadian Asset Management
53
Acadian Asset Management
Massachusetts
$510K -$2.77M -126,800 -85%
Deutsche Bank
54
Deutsche Bank
Germany
$509K +$217K +9,903 +83%
GAM
55
Gotham Asset Management
New York
$504K -$389K -17,785 -45%
DekaBank Deutsche Girozentrale
56
DekaBank Deutsche Girozentrale
Germany
$458K +$429K +19,600 New
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$441K -$2.3K -105 -0.6%
TC
58
TFS Capital
Pennsylvania
$433K -$55.6K -2,544 -12%
HHC
59
Hutchin Hill Capital
New York
$411K +$385K +17,600 New
NG
60
NatWest Group
United Kingdom
$405K -$8.22K -376 -2%
Citigroup
61
Citigroup
New York
$389K -$1.18K -54 -0.3%
Nomura Holdings
62
Nomura Holdings
Japan
$388K +$368K +16,829 New
QIM
63
Quest Investment Management
Oregon
$387K -$13.9K -635 -4%
NFA
64
Nationwide Fund Advisors
Ohio
$342K +$1.9K +87 +0.6%
Swiss National Bank
65
Swiss National Bank
Switzerland
$339K +$63.4K +2,900 +25%
Jennison Associates
66
Jennison Associates
New York
$336K -$11M -503,151 -97%
VOYA Investment Management
67
VOYA Investment Management
Georgia
$332K
MLICM
68
Metropolitan Life Insurance Company (MetLife)
New York
$328K -$86.3K -3,948 -22%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$322K -$17.7K -810 -6%
MC
70
Menta Capital
California
$315K +$107K +4,900 +57%
BA
71
BlackRock Advisors
Delaware
$313K -$36.2K -1,655 -11%
AIG
72
American International Group
New York
$299K +$6.71K +307 +2%
IAM
73
Iridian Asset Management
Connecticut
$294K -$105K -4,819 -28%
SCA
74
Secor Capital Advisors
New York
$293K +$274K +12,522 New
Bank of Montreal
75
Bank of Montreal
Ontario, Canada
$285K +$32.6K +1,490 +14%

SGNT Hedge Fund Activity: Q1 2014 in Review

94 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) for Q1 2014, worth a combined $538M — down 3.9% from $560M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of SGNT and 14 opened new positions — a net loss of 5 holders — while 32 trimmed existing stakes and 38 added.

The largest buyer was Franklin Resources, adding an estimated $25.8M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $12.9M sold.

  • 94 institutional investors held SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) as of Q1 2014, down from 99 in Q4 2013.
  • Funds reported $538M of SAGENT PHARMACEUTICALS INC COM STK (DE) stock for Q1 2014, down 3.9% quarter-over-quarter.
  • 14 funds opened new SAGENT PHARMACEUTICALS INC COM STK (DE) positions in Q1 2014 and 19 closed out, a net change of -5 holders.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) buyer in Q1 2014 was Franklin Resources, an estimated $25.8M added.
  • The largest SAGENT PHARMACEUTICALS INC COM STK (DE) seller in Q1 2014 was Loomis, Sayles & Company, an estimated $12.9M sold.

Based on aggregated 13F filings for Q1 2014.